Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1996 May 18;312(7041):1274–1278. doi: 10.1136/bmj.312.7041.1274

What can be concluded from the Oxcheck and British family heart studies: commentary on cost effectiveness analyses.

D Wonderling 1, S Langham 1, M Buxton 1, C Normand 1, C McDermott 1
PMCID: PMC2351093  PMID: 8634618

Abstract

OBJECTIVES--To provide a commentary on the economic evaluations of the Oxcheck and British family heart studies: direct comparison of their relative effectiveness and cost effectiveness; comparisons with other interventions; and consideration of problems encountered. DESIGN--Modelling from cost and effectiveness data to estimate of cost per life year gained. SUBJECTS--Middle aged men and women. INTERVENTIONS--Screening for cardiovascular risk factors followed by appropriate lifestyle advice and drug intervention in general practice, and other primary coronary risk management strategies. MAIN OUTCOME MEASURES--Life years gained; cost per life year gained. RESULTS--Depending on the assumed duration of risk reduction, the programme cost per discounted life year gained ranged from 34,800 pounds for a 1 year duration to 1500 pounds for 20 years for the British family heart study and from 29,300 pounds to 900 pounds for Oxcheck. These figures exclude broader net clinical and cost effects and longer term clinical and cost effects other than coronary mortality. CONCLUSIONS--Despite differences in underlying methods, the estimates in the two economic analyses of the studies can be directly compared. Neither study was large enough to provide precise estimates of the overall net cost. Modelling to cost per life year gained provides more readily interpretable measures. These estimates emphasise the importance of the relatively weak evidence on duration effect. Only if the effect lasts at least five years is the Oxcheck programme likely to be cost effective. The effect must last for about 10 years to justify the extra cost associated with the British family heart study.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Drummond M. F., Heyse J., Cook J., McGuire A. Selection of end points in economic evaluations of coronary-heart-disease interventions. Med Decis Making. 1993 Jul-Sep;13(3):184–190. doi: 10.1177/0272989X9301300303. [DOI] [PubMed] [Google Scholar]
  2. Field K., Thorogood M., Silagy C., Normand C., O'Neill C., Muir J. Strategies for reducing coronary risk factors in primary care: which is most cost effective? BMJ. 1995 Apr 29;310(6987):1109–1112. doi: 10.1136/bmj.310.6987.1109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Kristiansen I. S., Eggen A. E., Thelle D. S. Cost effectiveness of incremental programmes for lowering serum cholesterol concentration: is individual intervention worth while? BMJ. 1991 May 11;302(6785):1119–1122. doi: 10.1136/bmj.302.6785.1119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Langham S., Thorogood M., Normand C., Muir J., Jones L., Fowler G. Costs and cost effectiveness of health checks conducted by nurses in primary care: the Oxcheck study. BMJ. 1996 May 18;312(7041):1265–1268. doi: 10.1136/bmj.312.7041.1265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Mason J., Drummond M., Torrance G. Some guidelines on the use of cost effectiveness league tables. BMJ. 1993 Feb 27;306(6877):570–572. doi: 10.1136/bmj.306.6877.570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Nissinen A., Tuomilehto J., Kottke T. E., Puska P. Cost-effectiveness of the North Karelia Hypertension Program. 1972-1977. Med Care. 1986 Aug;24(8):767–780. doi: 10.1097/00005650-198608000-00012. [DOI] [PubMed] [Google Scholar]
  7. Parsonage M., Neuburger H. Discounting and health benefits. Health Econ. 1992 Apr;1(1):71–76. doi: 10.1002/hec.4730010110. [DOI] [PubMed] [Google Scholar]
  8. Stott N. Screening for cardiovascular risk in general practice. BMJ. 1994 Jan 29;308(6924):285–286. doi: 10.1136/bmj.308.6924.285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Tunstall-Pedoe H. The Dundee coronary risk-disk for management of change in risk factors. BMJ. 1991 Sep 28;303(6805):744–747. doi: 10.1136/bmj.303.6805.744. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Weinstein M. C., Stason W. B. Cost-effectiveness of interventions to prevent or treat coronary heart disease. Annu Rev Public Health. 1985;6:41–63. doi: 10.1146/annurev.pu.06.050185.000353. [DOI] [PubMed] [Google Scholar]
  11. Wonderling D., McDermott C., Buxton M., Kinmonth A. L., Pyke S., Thompson S., Wood D. Costs and cost effectiveness of cardiovascular screening and intervention: the British family heart study. BMJ. 1996 May 18;312(7041):1269–1273. doi: 10.1136/bmj.312.7041.1269. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES